title: Effects of enzyme induction therapy on glucose and drug metabolism in obese mice model of non-insulin dependent diabetes mellitus.
abstract: We evaluated the effects of phenobarbital, an inducer, on plasma glucose and serum immunoreactive insulin levels and on hepatic glucose and drug metabolism using an animal model of non-insulin dependent diabetes mellitus. Genetically obese (ob/ob) mice, characterized by hyperglycaemia, hyperinsulinaemia, fatty liver and obesity were selected. The impairment of diabetic state with age was associated with increased activities of NADPH producing enzymes, whereas mixed function oxidase system remained unaltered. Phenobarbital reduced serum immunoreactive insulin and plasma glucose levels and decreased gluconeogenesis. Hepatic glucose phosphorylating enzyme activity increased and glucose releasing enzyme activity decreased. The demand for NADPH in drug oxidation reactions, caused by the induction phenomenon, was reflected in the elevated activities of the NADPH producing enzymes in pentose phosphate pathway and in the activities of isocitrate dehydrogenase and malic enzyme from mitochondrial oxidation reactions. Glucose metabolism of lean littermates indicated that phenobarbital induction normalizes impaired intracellular glucose handling but leaves normal glucose metabolism unaltered. Hepatic glucose production rate was related to plasma glucose, NADPH producing enzyme activities and cytochrome P450 content in the obese and lean mice.
authors.affiliation: Department of Internal Medicine, University of Oulu, Finland.
authors.forename: I
authors.initials: I
authors.lastname: Karvonen
authors.forename: J H
authors.initials: JH
authors.lastname: Stengård
authors.forename: R
authors.initials: R
authors.lastname: Huupponen
authors.forename: F G
authors.initials: FG
authors.lastname: Stenbäck
authors.forename: E A
authors.initials: EA
authors.lastname: Sotaniemi
mesh_terms: D000818:Animals; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D003920:Diabetes Mellitus / Q000201:enzymology / Q000473:pathology; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology* / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000201:enzymology* / Q000473:pathology; D004790:Enzyme Induction; D005941:Glucokinase / Q000096:biosynthesis; D005947:Glucose / Q000378:metabolism*; D005954:Glucosephosphate Dehydrogenase / Q000096:biosynthesis; D006593:Hexokinase / Q000096:biosynthesis; D007521:Isocitrate Dehydrogenase / Q000096:biosynthesis; D008099:Liver / Q000187:drug effects / Q000201:enzymology*; D008291:Malate Dehydrogenase / Q000096:biosynthesis; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL / Q000378:metabolism; D008820:Mice, Obese / Q000378:metabolism*; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology*; D009251:NADPH-Ferrihemoprotein Reductase / Q000378:metabolism; D009765:Obesity; D010634:Phenobarbital / Q000494:pharmacology*; D010734:Phosphogluconate Dehydrogenase / Q000096:biosynthesis
chemical_list: D003577:Cytochrome P-450 Enzyme System; D008291:Malate Dehydrogenase; D007521:Isocitrate Dehydrogenase; D010734:Phosphogluconate Dehydrogenase; D005954:Glucosephosphate Dehydrogenase; D009251:NADPH-Ferrihemoprotein Reductase; D006593:Hexokinase; D005941:Glucokinase; D005947:Glucose; D010634:Phenobarbital